Clinical Trials Browser

INDUSTRY × patritumab deruxtecan × Clear all

NCT04165070 2026-03-16

MK-3475-01A

Phase 1/2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06445972 2026-03-16

MK-3475-06D

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06469944 2026-03-16

MK-3475-06C

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06596694 2026-03-16

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Phase 1/2 Recruiting

Gastrointestinal

Gastrointestinal Neoplasms

NCT07060807 2026-03-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Phase 3 Recruiting

Breast Neoplasms

NCT07286149 2026-03-16

MK-3475-01F

Phase 1/2 Recruiting

Lung Neoplasms

NCT06941272 2026-03-13

MK-9999-01C

Phase 1/2 Recruiting

Neoplasms

NCT03260491 2026-03-05

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT06731907 2026-02-18

MK-3475-01G

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06686394 2026-02-13

MK-1022-009

Phase 1/2 Recruiting

Breast Neoplasms

NCT06172478 2026-01-28

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 2 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04619004 2026-01-23

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

277 enrolled 16 charts

Non-Small Cell Lung Cancer Metastatic

NCT04676477 2025-06-22

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06099639 2025-06-08

Medical Access Program for Patritumab Deruxtecan

No longer available

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

NCT04479436 2025-05-18

A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

Phase 2 Terminated

40 enrolled 26 charts

Gastrointestinal

Colorectal Neoplasms

NCT05338970 2025-01-31

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Phase 3 Active not recruiting

Nonsquamous Non-small Cell Lung Cancer

NCT02980341 2024-10-30

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

Phase 1/2 Completed

182 enrolled 37 charts

Breast Neoplasms, Neoplasms